We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Morphic Holding Inc (MORF) USD0.0001

Sell:$28.05 Buy:$44.23 Change: $0.29 (1.05%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:$28.05
Buy:$44.23
Change: $0.29 (1.05%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Sell:$28.05
Buy:$44.23
Change: $0.29 (1.05%)
Market closed |  Prices as at close on 25 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Contact details

Address:
35 GATEHOUSE DRIVE A2
WALTHAM
02451
United States
Telephone:
+1 (781) 9960955
Website:
https://morphictx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MORF
ISIN:
US61775R1059
Market cap:
$1.44 billion
Shares in issue:
50.04 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Bruce Rogers
    President
  • Praveen Tipirneni
    Chief Executive Officer, Director
  • Marc Schegerin
    Chief Financial Officer, Chief Operating Officer
  • Robert Farrell
    Senior Vice President - Finance, Chief Accounting Officer
  • William DeVaul
    General Counsel, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.